<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of acute graft-versus-host disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of acute graft-versus-host disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of acute graft-versus-host disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Zeiser, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Negrin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nelson J Chao, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute graft-versus-host disease (aGVHD) is an adverse effect of allogeneic hematopoietic cell transplantation (HCT) that classically presents in the early post-transplantation period. It is primarily a T cell-mediated process that occurs when immune cells transplanted from a donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction in the recipient. Skin, gastrointestinal (GI) tract, and liver are the principal target organs in patients with aGVHD.
        </p>
        <p>
         The incidence of clinically significant aGVHD varies with the immunologic match between the recipient and the graft, transplant conditioning regimen, method of GVHD prophylaxis, and other factors. Treatment of aGVHD is determined by the affected organs, severity (ie, grade), and involvement of the GI tract.
        </p>
        <p>
         Management of aGVHD is reviewed here.
        </p>
        <p>
         Evaluation and diagnosis of aGVHD and prophylaxis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8072414">
         <span class="h1">
          DIAGNOSIS AND GRADING
         </span>
        </p>
        <p class="headingAnchor" id="H8072435">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin, gastrointestinal (GI) tract, and liver are the principal organs affected by aGVHD. The central nervous system, ovaries, testis, thymus, bone marrow, and kidney may also be affected, but clinical manifestations are less apparent and can be difficult to distinguish from drug toxicity and other conditions [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         The diagnosis of skin and liver aGVHD can be made clinically in patients with a classical presentation, but for intestinal GVHD and all other cases, the diagnosis should be confirmed by tissue biopsy. Clinical presentation and diagnostic criteria for aGVHD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classical presentation
         </strong>
         – The most common clinical manifestation of aGVHD is a maculopapular rash, usually occurring two to three weeks after allogeneic hematopoietic cell transplantation (HCT), around the time of the white blood cell engraftment. The diagnosis can be made clinically when aGVHD presents with a classic rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration within 100 days after allogeneic HCT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other presentations
         </strong>
         – When the presentation varies from the classic description, the diagnosis of aGVHD should be confirmed histologically so that alternative causes can be excluded. As examples, a skin rash alone may be caused by antibiotics or other drugs, diarrhea may be infectious in nature, and hyperbilirubinemia may be related to biliary sludge or as an adverse effect of drugs or
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         . In some cases, aGVHD can also begin &gt;100 days after transplantation; aGVHD can also occur after donor lymphocyte infusion (DLI). (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evaluation of diarrhea and abdominal pain that may be related to aGVHD is discussed below and in greater detail separately. (See
         <a class="local">
          'GI aGVHD'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Gastrointestinal tract'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3553404885">
         <span class="h2">
          Grading
         </span>
         <span class="headingEndMark">
          —
         </span>
         The grade of aGVHD and determining if there is GI tract involvement informs the approach to therapy. Details of grading aGVHD  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         ) are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Grading'
         </a>
         .)
        </p>
        <p>
         For treatment stratification, salient aspects of grading can be summarized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 1 aGVHD
         </strong>
         – Grade 1 aGVHD describes limited skin involvement (ie, stage 1 or 2 cutaneous aGVHD  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         )), without liver or GI tract involvement. All other manifestations of aGVHD and more severe cutaneous disease are considered grade 2 or higher.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade ≥2 aGVHD
         </strong>
         – Grade ≥2 aGVHD refers to any involvement beyond grade 1 (ie, &gt;50 percent cutaneous involvement or GI, liver, or other organ involvement).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GI aGVHD
         </strong>
         – Grading of GI involvement is based on the extent of diarrhea and abdominal pain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H263511838">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most treatments for aGVHD are based on suppression of donor T cells, which are primarily responsible for the syndrome. However, the same cells also mediate the immunologic reaction against the tumor (graft-versus-tumor [GVT] effect). As such, treatment should aim to balance the benefit of reducing GVHD with the potential harm of decreasing the GVT effect.
        </p>
        <p>
         We encourage participation in a clinical trial for management of aGVHD. Examples of relevant trials in the United States are available at:
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=3543" target="_blank">
          www.clinicaltrials.gov
         </a>
         .
        </p>
        <p>
         Our approach to management of aGVHD is consistent with guidelines proposed by the American Society of Blood and Marrow Transplantation [
         <a href="#rid4">
          4
         </a>
         ]; the British Committee for Standards in Hematology and the British Society for Bone Marrow Transplantation [
         <a href="#rid5">
          5
         </a>
         ]; and the European Group for Blood and Marrow Transplantation (EBMT) and European LeukemiaNet [
         <a href="#rid6">
          6
         </a>
         ]. Each institution that performs hematopoietic cell transplantation (HCT) must have guidelines for GVHD management that are approved by the Joint Accreditation Committee for ISCT Europe and EBMT (JACIE) or the Foundation for the Accreditation of Cell Therapy (FACT).
        </p>
        <p class="headingAnchor" id="H110015843">
         <span class="h2">
          Optimizing prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients who develop GVHD, the prophylaxis regimen should be reviewed and optimized.
        </p>
        <p>
         For patients who develop aGVHD when they are no longer receiving prophylaxis, the regimen should be restarted. Prophylaxis of GVHD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
         The calcineurin inhibitors (CNI),
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         (CsA) and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (Tac), are key components of most aGVHD prophylaxis regimens. Optimal prophylaxis involves monitoring blood level of the CNI [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Target trough levels of the CNIs are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CsA
         </strong>
         – The target concentration of CsA varies according to the time from transplantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A trough concentration of 200 to 300 ng/mL is targeted during the first three to four weeks after transplantation. If aGVHD does not develop, the target concentration is decreased to 100 to 200 ng/mL until three months after transplantation and then tapered further.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who develop aGVHD of any grade, the CsA dose should be adjusted to achieve a therapeutic level of 200 to 300 ng/mL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tac
         </strong>
         – The target trough range for Tac is 15 ng/mL.
        </p>
        <p>
        </p>
        <p>
         Anecdotal reports suggest that Tac may be effective in patients who developed aGVHD while receiving CsA prophylaxis. No prospective studies have reported the rate of salvage with Tac, but a retrospective study reported that 2 of 20 evaluable patients had a complete resolution of aGVHD after changing from CsA to Tac [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11941653">
         <span class="h2">
          Choice of initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of initial therapy for aGVHD depends on the extent and severity of symptoms (ie, grade) and whether the gastrointestinal tract (GI)  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         ) is involved:
        </p>
        <p class="headingAnchor" id="H2377270531">
         <span class="h3">
          Grade 1 aGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For grade 1 aGVHD, we suggest initial treatment with a topical steroid rather than systemic therapy, to limit the toxicity of systemic agents.
        </p>
        <p>
         Selection of a topical corticosteroid is discussed below. (See
         <a class="local">
          'Topical therapy'
         </a>
         below.)
        </p>
        <p>
         The GVHD prophylaxis regimen should also be optimized, as described above. (See
         <a class="local">
          'Optimizing prophylaxis'
         </a>
         above.)
        </p>
        <p>
         Vigilance for disease progression during treatment is important, to enable a rapid change to systemic therapy, if needed.
        </p>
        <p class="headingAnchor" id="H2889901816">
         <span class="h3">
          Grade ≥2 aGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For grade ≥2 aGVHD, we suggest treatment with a systemic glucocorticoid (GC; eg,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ), rather than an alternative approach. Systemic GCs have been widely adopted for treatment of grade ≥2 aGVHD and no other regimen has been proven superior for treatment of grade 2-4 aGVHD.
        </p>
        <p>
         Studies that compared initial treatment of aGVHD using a GC versus other regimens as front-line therapy for aGVHD include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GC plus MMF
         </strong>
         – A double-blind, phase 3 trial of a GC plus
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) versus a GC plus placebo (CTN 0802, NCT01002742) was closed for futility after accrual of 235 patients (of 372 planned participants) [
         <a href="#rid9">
          9
         </a>
         ]. There was no difference in day 56 GVHD-free survival (60 percent with GC plus MMF versus 54 percent with GC plus placebo), 12 month treatment-related mortality (TRM), 12 month chronic GVHD (cGVHD), grade ≥3 adverse events (AE), or incidence of severe infections or cytomegalovirus (CMV) reactivation [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GC plus itacitinib
         </strong>
         – A phase 3 trial (GRAVITAS-301) reported that GC plus itacitinib (JAK1 inhibitor) was not superior to GC plus placebo [
         <a href="#rid11">
          11
         </a>
         ]. The trial of 439 patients reported that GC/itacitinib was associated with 74 percent day 28 overall response rate (ORR), including 53 percent complete responses (CR), while GC/placebo was associated with 66 percent ORR and 40 percent CR. The incidence of grade ≥3 AEs (mostly cytopenias) was similar between trial arms (86 versus 82 percent, respectively), and TRM was 1 percent with itacitinib and 2 percent with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GC plus
         </strong>
         <strong>
          etanercept
         </strong>
         – Treatment of 61 patients with a GC plus
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         (recombinant human tumor necrosis factor [TNF]-alpha receptor fusion protein) was compared with treatment of a contemporaneous group of 99 patients who received
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         alone [
         <a href="#rid12">
          12
         </a>
         ]. GC/etanercept treatment was associated with superior day 100 overall survival (OS; 82 versus 66 percent) and a higher rate of day 28 CR (69 versus 33 percent); this effect was observed in recipients of related donor grafts (79 versus 39 percent) and recipients of unrelated donor grafts (53 versus 26 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GC plus various agents
         </strong>
         – A phase 2 study randomly assigned 180 patients to treatment with
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         plus either MMF,
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , denileukin diftitox (human interleukin-2 [IL-2] attached to diphtheria toxin), or
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         (purine analog) [
         <a href="#rid13">
          13
         </a>
         ]. MMF was associated with superior day 28 CR (60 percent) and nine month OS (64 percent), compared with etanercept (26 percent CR; 47 percent OS), denileukin diftitox (53 percent CR; 49 percent OS), or pentostatin (38 percent CR; 47 percent OS). Severe infections were reported in 44 percent of patients treated with MMF, 48 percent with etanercept, 62 percent with denileukin diftitox, and 57 percent with pentostatin.
        </p>
        <p>
        </p>
        <p>
         Administration, AEs, and outcomes with systemic GCs are discussed below. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2823609701">
         <span class="h3">
          GI aGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For aGVHD that affects the GI tract, we treat with a nonabsorbable oral steroid plus a systemic GC, rather than a systemic GC alone; the systemic GC should initially be given intravenously to avoid impaired absorption due to GI aGVHD. Addition of a nonabsorbable steroid to a systemic GC can decrease the dose and/or shorten the course of the systemic GC and was shown to improve survival and reduce aGVHD relapses in phase 3 trials [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
         Importantly, nonabsorbable oral steroids should not be used in patients with a suspected GI infection (eg, CMV colitis).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – We evaluate the cause of diarrhea/enterocolitis before treating with an oral nonabsorbable steroid. The cause can remain unclear, even with careful investigation and GI symptoms may be due to concurrent aGVHD and infection. A decision to add a nonabsorbable oral steroid must be balanced against the potential risks of exacerbating an undiagnosed infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally evaluate diarrhea in this setting with bacterial cultures and viral testing (eg, polymerase chain reaction [PCR] assays for CMV in peripheral blood, testing of stool specimens for adenovirus or rotavirus); we consider an intestinal biopsy for histologic analysis on a case-by-case basis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – The most commonly used nonabsorbable steroids are oral
         <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">
          beclomethasone
         </a>
         dipropionate (BDP) or
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         [
         <a href="#rid16">
          16,17
         </a>
         ]; these agents have not been compared directly in this setting. We generally begin a slow taper of the systemic GC after one week of treatment with the oral nonabsorbable steroid. Although these agents are described as "nonabsorbable" steroids, a small amount may be systemically absorbed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care for GI aGVHD
         </strong>
         – Patients with GI aGVHD may have malnutrition, protein-losing enteropathy, and/or abnormalities in magnesium, zinc, vitamin B12, and vitamin D [
         <a href="#rid18">
          18
         </a>
         ]. We generally request an evaluation by a nutritionist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most patients with GI aGVHD require supplementary nutritional support. We favor the enteral route, if tolerated, rather than
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         support. However, patients with diarrhea ≥500 mL/day should receive parenteral nutrition, with stepwise reintroduction of an oral diet once the diarrhea decreases to &lt;500 mL/day. (See
         <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">
          "The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         can reduce the amount of diarrhea, but it should be discontinued within 24 hours after the resolution of diarrhea to avoid the development of ileus [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse events
         </strong>
         – Oral nonabsorbable steroids are well-tolerated, but they must be used with caution in patients who may have an underlying GI infection. Patients who received prolonged BDP treatment (seven weeks) often developed biochemical evidence of abnormal hypothalamic-pituitary axis suppression, but no other toxicity was reported [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Oral nonabsorbable steroids can increase the rate of response and enable lower doses of systemic GCs:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A phase 3 trial reported that, compared with placebo, oral BDP achieved superior survival and more effectively prevented relapse of GI GVHD [
         <a href="#rid15">
          15
         </a>
         ]. The trial enrolled 129 patients with anorexia, vomiting, and diarrhea, but it excluded patients with severe aGVHD (eg, abdominal pain, secretory diarrhea &gt;1 L/day, intestinal bleeding, or liver and skin GVHD). Patients were treated with systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         for 10 days, followed by a rapid taper of prednisone and random assignment to 50 days of treatment with either oral BDP or an oral placebo. The risk of treatment failure at day 80 was lower with BDP (hazard ratio [HR] 0.37 [95% CI 0.20-0.69]) compared with placebo. By day 200, 5 patients treated with BDP had died, compared with 16 deaths on placebo (HR 0.33 [95% CI 0.12-0.89]); the HR for death at 12 months was 0.54 (95% CI 0.30-0.99). Among the 47 recipients of unrelated and HLA-mismatched grafts, 4 percent of patients treated with BDP died, compared with 42 percent of patients who received placebo (HR 0.09 [95% CI 0.01-0.70]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An earlier phase 3 trial that randomly assigned 60 patients to BDP versus placebo (for 30 days) also reported that BDP was associated with improved of survival and response [
         <a href="#rid14">
          14
         </a>
         ]. Treatment response at day 30 was 71 percent with BDP versus 41 percent with placebo.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H51897773">
         <span class="h1">
          RESPONSE ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to treatment is monitored to enable dose adjustment and to limit toxicity.
        </p>
        <p>
         On days 5 and 7 of treatment, a formal assessment of skin, liver, and gastrointestinal tract aGVHD severity (grade)  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         ) is performed. In addition, the patient is evaluated daily for symptoms, infections, and disease- or treatment-related complications.
        </p>
        <p>
         Patients with progression of disease by day 5 or no response by day 7 are considered to have glucocorticoid-resistant aGVHD [
         <a href="#rid22">
          22-26
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoid-resistant aGVHD'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3359917336">
         <span class="h1">
          TREATMENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3371320648">
         <span class="h2">
          Topical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical steroids are the mainstay of treatment for mild cutaneous aGVHD (ie, grade 1). (See
         <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">
          "Cutaneous manifestations of graft-versus-host disease (GVHD)"
         </a>
         .)
        </p>
        <p>
         Topical steroids differ in strength, vehicle (eg, ointments, creams, lotions), and method of application  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 2
         </a>
         ). We generally apply a mid- or high-potency topical steroid twice daily to moist skin and cover the area with warm, wet towels ("wet wrap"). Selection of a topical steroid should consider whether the affected skin is predominantly moist versus dry and hairy versus non-hairy. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Corticosteroid selection and administration'
         </a>
         .)
        </p>
        <p>
         Skin moisturizers, nonirritating creams, and antihistamines can help to relieve pruritus. (See
         <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">
          "Cutaneous manifestations of graft-versus-host disease (GVHD)", section on 'Ancillary measures in chronic graft-versus-host disease'
         </a>
         .)
        </p>
        <p>
         For
         <strong>
         </strong>
         grade 1 aGVHD that has not responded adequately to topical steroids (see
         <a class="local">
          'Response assessment'
         </a>
         above), we favor treatment with topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         or oral
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , rather than a systemic glucocorticoid (GC). Clinical practice varies [
         <a href="#rid5">
          5,27
         </a>
         ], but options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          tacrolimus
         </strong>
         (0.1 percent for adults) is applied twice daily until resolution of symptoms. If the disease flares upon discontinuation, topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         can be restarted at a lower dose (0.03 percent) and then discontinued upon resolution of symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ruxolitinib
         </strong>
         – Oral
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         has shown efficacy for therapy-resistant grade ≥2 aGVHD of skin [
         <a href="#rid22">
          22
         </a>
         ]. Important cautions with ruxolitinib therapy are described below. (See
         <a class="local">
          'Ruxolitinib'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1516490828">
         <span class="h2">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic GCs are standard initial therapy for patients with grade ≥2 aGVHD [
         <a href="#rid4">
          4,5,16,27
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          Methylprednisolone
         </a>
         is often used to treat aGVHD, but the preferred agent, dose, and schedule vary among institutions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally begin treatment with
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         2 mg/kg/day in divided doses and continue it for several weeks in patients whose aGVHD is responding  (
         <a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid28">
          28
         </a>
         ]. It is then tapered gradually over several months to prevent a disease flare.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients whose aGVHD progresses by day 5 or with no response by day 7 are considered to have GC-resistant GVHD and are treated as described below. (See
         <a class="local">
          'Glucocorticoid-resistant aGVHD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects (AE)
         </strong>
         – Systemic GCs are associated with immunosuppression, increased infections, metabolic, neuropsychiatric, and other AEs, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Systemic GCs are generally associated with 25 to 40 percent complete response (CR) of aGVHD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A phase 3 trial reported that, compared with higher doses, lower-dose systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         achieved comparable survival but was associated with increased need for secondary immunosuppressive therapy [
         <a href="#rid29">
          29
         </a>
         ]. Treatment in this trial was stratified according to the stage of aGVHD:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Grade 2b-4
         </strong>
         – There was no difference in overall survival (OS) at six weeks or cumulative
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose for patients who were randomly assigned to prednisone 2 mg/kg/day versus 1 mg/kg/day. For the 53 patients with skin-predominant grade 2b disease, there was no significant difference in progression to grade 3-4 aGVHD (19 percent with the lower dose versus 7 percent with the higher dose), but lower-dose prednisone was associated with greater need for secondary immunosuppressive therapy (41 versus 7 percent). For gut-predominant aGVHD, there was no difference in need for secondary immunosuppressive therapy between trial arms.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Grade 2a
         </strong>
         – Patients with grade 2a disease (ie, rash involving &lt;50 percent of body surface area [BSA], stool &lt;1 L/day, no hepatic dysfunction) were randomly assigned to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg/day versus 0.5 mg/kg/day. For these 102 patients, there was no difference in OS, mean prednisone dose, disease progression, or the likelihood of requiring secondary systemic immunosuppressive therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A multicenter trial randomly assigned 95 patients with aGVHD to either low (2 mg/kg per day) or high (10 mg/kg per day) dose
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ]. There were no differences in three-year OS or overall response rate, but nearly half of patients in the low-dose group were switched to a higher dose because of lack of response by day 5 or disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A retrospective study analyzed transplant outcomes among 733 patients who received initial treatment with standard-dose GC (prednisone-equivalent dose of 2 mg/kg per day) versus low-dose (1 mg/kg per day) [
         <a href="#rid31">
          31
         </a>
         ]. Lower-dose treatment for patients with grade 1-2 aGVHD was not associated with increased mortality or decreased disease control, but it was associated with shorter hospitalizations and fewer invasive fungal infections and Gram-negative bacteremia. However, the pace of disease and physician preference likely affected the choice of initial GC dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Studies that used high doses of intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (eg, 10 to 20 mg/kg/day) showed a high response rate but were complicated by opportunistic infections, interstitial pneumonitis, and recrudescence of GVHD upon dose reduction [
         <a href="#rid32">
          32,33
         </a>
         ]. Subsequent studies using intermediate doses of methylprednisolone (1.5 to 2 mg/kg) reported good response rates but poor outcomes for those with severe GVHD [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H615951248">
         <span class="h1">
          GLUCOCORTICOID-RESISTANT aGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoid (GC)-resistant aGVHD is defined as disease that progresses by day 5 or no response to treatment by day 7. (See
         <a class="local">
          'Response assessment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2483033272">
         <span class="h2">
          Choice of treatment for GC-resistant aGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For GC-resistant aGVHD, we suggest treatment with
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , rather than other agents, based on superior efficacy and modest toxicity in a phase 3 trial that compared ruxolitinib with best available therapy (BAT) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter phase 3 trial reported that
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         was superior to standard care for grade 2-4 GC-refractory aGVHD [
         <a href="#rid22">
          22
         </a>
         ]. In this trial, 309 patients ≥12 years old were randomly assigned (1:1) to ruxolitinib (10 mg by mouth, twice daily) versus the investigator's choice of therapy; control therapy was chosen by the investigator at the time of randomization from the following: anti-thymocyte globulin, extracorporeal photopheresis, mesenchymal stromal cells, low-dose
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , or
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At day 28, compared with the control group,
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         achieved superior overall response rate (ORR; 62 versus 39 percent; odds ratio 2.64 [95% CI 1.65-4.22]) and complete response (CR; 34 versus 19 percent) [
         <a href="#rid22">
          22
         </a>
         ]. Superiority of ruxolitinib was maintained at day 56 (40 versus 22 percent) with all grades of disease and affected organs, but the duration of follow-up was not sufficient to assess an impact on survival. By day 56, more patients who were treated with ruxolitinib had discontinued GCs (21 versus 14 percent) and fewer patients discontinued therapy for lack of efficacy (72 versus 85 percent). The most common grade ≥3 adverse effects (AEs) with ruxolitinib were thrombocytopenia, anemia, and cytomegalovirus (CMV) infection; there was no difference in the frequency of infections (approximately one-fifth for both groups). Other studies report similar benefits and toxicity of ruxolitinib for aGVHD in adults and children [
         <a href="#rid23">
          23-26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1803965710">
         <span class="h2">
          Ruxolitinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is a selective inhibitor of Janus kinase (JAK)1 and JAK2. Signaling through JAKs and signal transducers and activators of transcription (STAT) contributes to inflammation and tissue damage in GVHD. (See
         <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">
          "Pathogenesis of graft-versus-host disease (GVHD)", section on 'Acute GVHD'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is administered by mouth (10 mg twice daily) [
         <a href="#rid23">
          23
         </a>
         ]. Dose adjustments may be required for cytopenias and for renal or hepatic impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who respond within eight weeks of therapy,
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         may be tapered gradually (eg, 5 mg every three weeks). The taper must be gradual, because a "withdrawal syndrome" that resembles systemic inflammatory response syndrome can occur when ruxolitinib is discontinued abruptly or tapered too quickly [
         <a href="#rid36">
          36,37
         </a>
         ]. Patients should be monitored for a withdrawal-like syndrome and ruxolitinib should be resumed in patients with significant withdrawal symptoms or recrudescence of aGVHD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Toxicity includes cytopenias, liver dysfunction, neurologic complaints, reactivation of viral infections, and bacterial or fungal infections.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is approved by the US Food and Drug Administration [
         <a href="#rid23">
          23
         </a>
         ] and the European Medicines Agency for treatment of GC-refractory aGVHD in patients ≥12 years.
        </p>
        <p class="headingAnchor" id="H3168276552">
         <span class="h2">
          Other second-line treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus treatment for GC-resistant aGVHD beyond
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         . The preferred treatment varies among institutions and is influenced by availability, cost, and patient preference.
        </p>
        <p class="headingAnchor" id="H1100375258">
         <span class="h3">
          Mycophenolate mofetil (MMF)
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMF is a selective inhibitor of purine synthesis in lymphocytes.
        </p>
        <p>
         MMF was associated with 31 percent ORR of 13 patients with GC-refractory aGVHD, including 31 percent ORR with skin involvement, 44 percent of nine patients with liver involvement, and 23 percent of nine patients with gastrointestinal (GI) tract involvement [
         <a href="#rid38">
          38
         </a>
         ]. In a prospective study, oral MMF was associated with 47 percent ORR (including 31 percent CR) in 19 patients with GC-refractory aGVHD; similar outcomes were seen in a retrospective analysis of 29 additional patients [
         <a href="#rid39">
          39
         </a>
         ]. MMF was associated with a response in 60 percent of 10 patients with GC-refractory aGVHD [
         <a href="#rid40">
          40
         </a>
         ]. Four of six patients with GC-refractory aGVHD responded to MMF in a small prospective study; AEs included infections, diarrhea, and neutropenia [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         A phase 3 trial that evaluated MMF for initial treatment of aGVHD is described above. (See
         <a class="local">
          'Grade ≥2 aGVHD'
         </a>
         above.)
        </p>
        <p>
         Details of MMF administration and AEs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1849907918">
         <span class="h3">
          Etanercept
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          Etanercept
         </a>
         is a recombinant human tumor necrosis factor (TNF)-alpha receptor fusion protein.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          Etanercept
         </a>
         for GC-refractory aGVHD is associated with infections and relapse of the underlying malignancy. AEs associated with etanercept are described separately. (See
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study that included 13 patients with GC-refractory aGVHD reported that
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         (25 mg given subcutaneously twice weekly for four weeks, followed by 25 mg weekly for four weeks) resulted in 46 percent ORR (including 31 percent CR); responses were more common with gut involvement [
         <a href="#rid42">
          42
         </a>
         ]. CMV reactivation occurred in one-half and bacterial and fungal infections were also seen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective, single-institution study reported 81 percent ORR in 16 patients with predominantly visceral GC-refractory aGVHD who were treated with
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , anti-thymocyte globulin (ATG), and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (Tac), with or without MMF [
         <a href="#rid43">
          43
         </a>
         ]. Progressive GVHD occurred in two patients, infection in five, and relapse of the underlying malignancy in one.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase 2 study of
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         plus daclizumab (IL-2 receptor antibody) in 21 patients with GC-refractory aGVHD reported 67 percent ORR (including 38 percent CR) [
         <a href="#rid44">
          44
         </a>
         ]. Treatment-related mortality (TRM) due to infectious complications occurred in 53 percent, aGVHD-associated organ failure in 14 percent, and relapse of the underlying malignancy in 14 percent; progression to chronic GVHD was seen in 57 percent.
        </p>
        <p>
        </p>
        <p>
         Studies that included
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         for initial treatment of aGVHD are described above. (See
         <a class="local">
          'Grade ≥2 aGVHD'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3032596691">
         <span class="h3">
          Pentostatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          Pentostatin
         </a>
         is
         <strong>
         </strong>
         a purine analog that inhibits T cell proliferation and function.
        </p>
        <p>
         The standard dose of
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         is 1.5 mg/m
         <sup>
          2
         </sup>
         /day intravenously on days 1 to 3 of each 14-day cycle. Pentostatin should be used with caution in patients with renal insufficiency; 50 percent dose reduction has been suggested for patients with an estimated creatinine clearance of 30 to 50 mL/min [
         <a href="#rid45">
          45
         </a>
         ]. Administration and AEs associated with pentostatin are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4535.html" rel="external">
          "Treatment of hairy cell leukemia", section on 'Pentostatin'
         </a>
         .)
        </p>
        <p>
         A phase 1 study explored the efficacy of
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         for treatment of aGVHD [
         <a href="#rid46">
          46
         </a>
         ]. CR was noted in 14 of 22 patients with GC-refractory aGVHD at a maximal tolerated dose of 1.5 mg/m
         <sup>
          2
         </sup>
         intravenously per day for three days. Lymphopenia was universal, but pentostatin was otherwise well tolerated.
        </p>
        <p>
         A study that included
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         for initial treatment of aGVHD is described above. (See
         <a class="local">
          'Grade ≥2 aGVHD'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2513795385">
         <span class="h3">
          Alpha-1 antitrypsin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alpha-1 antitrypsin (AAT) is a circulating protease inhibitor that protects tissues from proteolytic degradation, suppresses proinflammatory cytokines, and alters ratios of effector T cells to regulatory T cells [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         A multicenter phase 2 study that treated 40 patients with GC-resistant aGVHD using intravenous AAT (60 mg/kg per day twice weekly, for up to four weeks) reported 65 percent ORR (including 35 percent CR) [
         <a href="#rid48">
          48
         </a>
         ]. Nearly three-quarters of responding patients sustained their responses at day 60 without intervening immunosuppression. Infection-related TRM was 10 percent at six months and there were no drug-related AEs. A phase 1 study of 12 patients reported similar responses to AAT with no significant AEs [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3809332709">
         <span class="h3">
          Sirolimus
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          Sirolimus
         </a>
         is a lipophilic macrolide that inhibits mammalian targets of rapamycin (mTOR).
        </p>
        <p>
         Importantly,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         has been associated with hepatic sinusoidal obstruction syndrome (SOS; also called veno-occlusive disease) following myeloablative conditioning regimens, especially when myeloablative doses of
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         were employed. (See
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease", section on 'Sirolimus'
         </a>
         .)
        </p>
        <p>
         A study of 21 patients with grade 3-4 aGVHD reported 57 percent ORR (including 33 percent CR) [
         <a href="#rid50">
          50
         </a>
         ].
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          Sirolimus
         </a>
         was given as a loading dose of 15 mg/m
         <sup>
          2
         </sup>
         followed by a daily dose of 5 mg/m
         <sup>
          2
         </sup>
         daily for 13 days or at a dose of 4 to 5 mg/m
         <sup>
          2
         </sup>
         without a loading dose for 14 days. Myelosuppression was common, two patients developed seizures, and five patients developed hemolytic-uremic syndrome.
        </p>
        <p class="headingAnchor" id="H1324010217">
         <span class="h3">
          Extracorporeal photopheresis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extracorporeal photopheresis (ECP) uses autologous peripheral lymphocytes that are collected by apheresis, incubated with 8-methoxypsoralen, and irradiated with ultraviolet A. Better results are expected in patients with aGVHD limited to the skin. Treatment with ECP is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16616.html" rel="external">
          "Treatment of Sézary syndrome", section on 'Extracorporeal photopheresis (ECP)'
         </a>
         .)
        </p>
        <p>
         Studies of ECP for aGVHD include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A review of 11 studies employing ECP (76 patients total) for aGVHD reported CR to skin, gut, and liver involvement in 67, 54, and 38 percent of patients, respectively [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective analysis of 98 patients with GC-refractory aGVHD treated with ECP (57 patients) or anticytokine therapy (
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         or inolimomab, 41 patients) reported that ECP was associated with superior rates of CR (54 versus 20 percent) and OS (hazard ratio 2.12 [95% CI 1.13-3.96]) [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study reported 50 percent ORR (including 28 percent CR) at three months in 30 patients treated with ECP [
         <a href="#rid53">
          53
         </a>
         ]. Treatment of 21 patients reported CR in 100, 67, and 12 percent of patients with grades 2, 3, and 4 aGVHD, respectively [
         <a href="#rid54">
          54
         </a>
         ]. Other studies have reported similar outcomes with ECP for GC-refractory aGVHD [
         <a href="#rid55">
          55-60
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Italian and British experts have created consensus statements for use of ECP with GVHD [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H519895832">
         <span class="h3">
          Anti-thymocyte globulin (ATG)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who did not receive ATG as part of their prophylaxis regimen, ATG can be considered for management of GC-refractory aGVHD. (See
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease", section on 'Antithymocyte globulin (ATG)'
         </a>
         .)
        </p>
        <p>
         A study that included ATG plus
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         is described above. (See
         <a class="local">
          'Etanercept'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1899243805">
         <span class="h3">
          Brentuximab vedotin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">
          Brentuximab vedotin
         </a>
         (BV)
         <strong>
         </strong>
         is a CD30-directed monoclonal antibody-drug conjugate. A multicenter, phase 1 study reported 39 percent ORR (including 15 percent CR) using biweekly BV treatment in 28 patients with GC-refractory aGVHD [
         <a href="#rid63">
          63
         </a>
         ]. Treatment with a weekly dosing schedule of BV was associated with profound neutropenia, including two deaths.
        </p>
        <p class="headingAnchor" id="H1200127258">
         <span class="h3">
          Monoclonal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monoclonal antibodies (Mabs)
         <strong>
         </strong>
         that have been evaluated for GC-resistant aGVHD include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interleukin-2 receptor (CD25 alpha) antibodies
         </strong>
         – Therapeutic antibodies against the IL-2 receptor (IL-2R; CD25) include the humanized Mabs, daclizumab and
         <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">
          basiliximab
         </a>
         , and the mouse Mab, inolimomab. IL-2R blockade prevents T cell proliferation and may reduce GVHD, but T regulatory cells (Tregs) are important in modulating GVHD and their removal may contribute to inferior outcomes. (See
         <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">
          "Pathogenesis of graft-versus-host disease (GVHD)", section on 'Histocompatibility'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">
          "Liver transplantation in adults: Initial and maintenance immunosuppression", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Therapeutic antibodies directed against IL-2R have not shown greater efficacy or safety compared with other treatments for GC-resistant acute GVHD. Examples of such studies include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">
          Basiliximab
         </a>
         was associated with 83 percent ORR (including 18 percent CR) in 23 patients with GC-refractory acute GVHD, with an 18 percent CR and 65 percent partial response (PR) rate [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an open-label multicenter trial, OS, time to treatment failure, and AEs were similar among 100 patients who were randomly assigned to inolimomab versus ATG for GC-resistant aGVHD [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment of 62 patients with daclizumab reported 69 percent CR of aGVHD, with higher response rates in those with fewer involved organs and less extensive skin involvement; nevertheless, most patients went on to develop extensive cGVHD [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A phase 3 trial that compared GC alone versus GC plus daclizumab for initial treatment of aGVHD was terminated when an interim analysis showed significantly worse OS at day 100 and at one year for patients treated with the combination [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Daclizumab was withdrawn from market worldwide because of safety concerns.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tocilizumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          Tocilizumab
         </a>
         is an anti-interleukin-6 receptor antibody. Administration and AEs with tocilizumab are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">
          "Overview of biologic agents in the rheumatic diseases", section on 'Tocilizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Responses were seen in four of six patients treated with
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         for GC-refractory aGVHD [
         <a href="#rid68">
          68
         </a>
         ]. Infections were the most common AE, but some patients had transient elevations in liver function tests.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alemtuzumab
         </strong>
         – The humanized CD52-directed monoclonal antibody,
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         was associated with 70 percent ORR (including 35 percent CR) in 20 patients with grade 3-4 GC-resistant aGVHD involving the gut [
         <a href="#rid69">
          69
         </a>
         ]. CMV reactivation, bacterial infection, and invasive aspergillosis were frequent AEs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1652862227">
         <span class="h3">
          Mesenchymal stromal cells (MSCs)
         </span>
         <span class="headingEndMark">
          —
         </span>
         MSCs that are present in bone marrow provide growth factors that are needed for hematopoiesis; can differentiate to fibroblasts, adipocytes, osteoblasts, and/or chondrocytes in vitro and in vivo; and induce CD4+/CD25+/FOXP3+ regulatory T cells (Tregs) [
         <a href="#rid70">
          70-74
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase 3 trial that compared standard care plus either MSCs versus placebo in 244 patients with GC-refractory GVHD reported no significant difference in CR at four weeks (40 versus 28 percent, respectively) or infections [
         <a href="#rid75">
          75
         </a>
         ]. However, treatment with MSCs was superior for GC-refractory GVHD that affected all three organs (skin, liver, and gut; 63 versus 0 percent ORR), liver (76 versus 47 percent ORR and 29 versus 5 percent CR at four weeks), and gut (82 versus 68 percent); there was also less progression of liver GVHD at two and four weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase 2 study of ex vivo expanded MSCs (one to five doses with median 1.4 x 10
         <sup>
          6
         </sup>
         cells/kg from a matched sibling donor, haploidentical donor, or third-party human leukocyte antigen [HLA]-mismatched donor) reported 71 percent ORR (including 54 percent CR) in 55 patients with GC-resistant aGVHD [
         <a href="#rid74">
          74
         </a>
         ]. There were no AEs during or immediately after MSC infusions and responses were not related to the degree of immunologic match.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ORR and CR were 94 and 77 percent, respectively, in 31 evaluable patients with de novo grade 2-4 aGVHD who were treated with systemic GC plus third-party, unmatched MSCs [
         <a href="#rid76">
          76
         </a>
         ]. There were no infusional AEs and there was no difference in safety or efficacy using treatment with low versus high doses of MSCs.
        </p>
        <p>
        </p>
        <p>
         MSCs derived from placenta also show promise for treating aGVHD, based on small, preliminary studies [
         <a href="#rid77">
          77,78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17612833">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Graft-versus-host disease (GVHD)
         </strong>
         – GVHD occurs after allogeneic hematopoietic cell transplantation (HCT), when donor immune cells in the graft recognize the transplant recipient (host) as foreign. Acute GVHD (aGVHD), which principally affects skin, gastrointestinal (GI) tract, and liver, is primarily a T cell-mediated process. (See
         <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">
          "Pathogenesis of graft-versus-host disease (GVHD)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Preferred treatments for aGVHD vary according to the affected organs and the extent and severity of signs and symptoms  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Optimize prophylaxis
         </strong>
         – For treatment of any grade of aGVHD, the prophylaxis regimen should be optimized by measuring blood levels of the calcineurin inhibitor (ie,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ). (See
         <a class="local">
          'Optimizing prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Grade 1
         </strong>
         – For patients with mild cutaneous (grade 1) aGVHD, we suggest treatment of symptomatic sites with topical steroids, rather than systemic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Grade 1 aGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Grade ≥2
         </strong>
         – For grade ≥2 GVHD, we suggest treatment with a systemic glucocorticoid (GC), rather than other agents or regimens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Grade ≥2 aGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          GI involvement
         </strong>
         – For patients with aGVHD that involves the GI tract, we suggest a systemic GC plus an oral nonabsorbable steroid, rather than systemic therapy alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Most patients will require supplemental nutrition and they may need
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         to control diarrhea. (See
         <a class="local">
          'GI aGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment response
         </strong>
         – Response of aGVHD is assessed on days 5 and 7 of treatment  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         ); in addition, the patient is evaluated daily for symptoms, infections, and disease-related complications. (See
         <a class="local">
          'Response assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic therapy
         </strong>
         – The most widely used systemic GC is
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         . For patients who are responding, the GC is continued for several weeks and then gradually tapered over months. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GC-refractory GVHD
         </strong>
         – Patients with progression of aGVHD by day 5 or no response by day 7 are considered to have GC-resistant aGVHD. (See
         <a class="local">
          'Glucocorticoid-resistant aGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For treatment of GC-refractory aGVHD, we suggest
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , rather than other treatments (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For GC-refractory aGVHD does not respond or progresses after
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , there is no consensus treatment; options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil – (See
         <a class="local">
          'Mycophenolate mofetil (MMF)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          Etanercept
         </a>
         – (See
         <a class="local">
          'Etanercept'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          Pentostatin
         </a>
         – (See
         <a class="local">
          'Pentostatin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Alpha-1 antitrypsin – (See
         <a class="local">
          'Alpha-1 antitrypsin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          Sirolimus
         </a>
         – (See
         <a class="local">
          'Sirolimus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Extracorporeal photopheresis – (See
         <a class="local">
          'Extracorporeal photopheresis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Other agents – (See
         <a class="local">
          'Anti-thymocyte globulin (ATG)'
         </a>
         above and
         <a class="local">
          'Brentuximab vedotin'
         </a>
         above and
         <a class="local">
          'Monoclonal antibodies'
         </a>
         above and
         <a class="local">
          'Mesenchymal stromal cells (MSCs)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Mathew NR, Vinnakota JM, Apostolova P, et al. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. J Clin Invest 2020; 130:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad AG, Alyea EP 3rd, Wen PY, et al. Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation. J Clin Oncol 2009; 27:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimoji S, Hashimoto D, Tsujigiwa H, et al. Graft-versus-host disease targets ovary and causes female infertility in mice. Blood 2017; 129:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; 7:e157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruutu T, Gratwohl A, Niederwieser D, et al. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. Bone Marrow Transplant 2017; 52:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolaños-Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 2014; 124:3221.
          </a>
         </li>
         <li class="breakAll">
          https://clinicaltrials.gov/ct2/show/results/NCT01002742 (Accessed on March 08, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiser R, Socié G, Schroeder MA, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol 2022; 9:e14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111:2470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998; 115:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109:4557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014; 49:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim RB, Abidi MH, Cronin SM, et al. Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Meij BS, de Graaf P, Wierdsma NJ, et al. Nutritional support in patients with GVHD of the digestive tract: state of the art. Bone Marrow Transplant 2013; 48:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ippoliti C, Champlin R, Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15:3350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckman RA, Siden R, Yanik GA, Levine JE. Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child. J Pediatr Hematol Oncol 2000; 22:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ippoliti C, Neumann J. Octreotide in the management of diarrhea induced by graft versus host disease. Oncol Nurs Forum 1998; 25:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med 2020; 382:1800.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202192s017lbl.pdf (Accessed on July 11, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29:2062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khandelwal P, Teusink-Cross A, Davies SM, et al. Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients. Biol Blood Marrow Transplant 2017; 23:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagasia M, Perales MA, Schroeder MA, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 2020; 135:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolff D, Ayuk F, Elmaagacli A, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant 2013; 19:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109:4119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mielcarek M, Furlong T, Storer BE, et al. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica 2015; 100:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92:2288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113:2888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacigalupo A, van Lint MT, Frassoni F, et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut 1983; 46:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanojia MD, Anagnostou AA, Zander AR, et al. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984; 37:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neudorf S, Filipovich A, Ramsay N, Kersey J. Prevention and treatment of acute graft-versus-host disease. Semin Hematol 1984; 21:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori Y, Ikeda K, Inomata T, et al. Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant 2016; 51:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004; 73:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009; 44:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krejci M, Doubek M, Buchler T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takami A, Mochizuki K, Okumura H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 2006; 83:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy GA, Butler J, Western R, et al. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006; 37:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poi MJ, Hofmeister CC, Johnston JS, et al. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet 2013; 52:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolaños-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23:2661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A 2012; 109:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magenau JM, Goldstein SC, Peltier D, et al. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood 2018; 131:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcondes AM, Hockenbery D, Lesnikova M, et al. Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin. Biol Blood Marrow Transplant 2016; 22:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72:1924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagasia M, Greinix H, Robin M, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant 2013; 19:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hautmann AH, Wolff D, Hahn J, et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. Bone Marrow Transplant 2013; 48:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96:2426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall SR. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besnier DP, Chabannes D, Mahé B, et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997; 64:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith EP, Sniecinski I, Dagis AC, et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998; 4:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92:3098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanold J, Merlin E, Halle P, et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007; 47:2276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubegni P, Feci L, Poggiali S, et al. Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form. Br J Dermatol 2013; 169:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierelli L, Perseghin P, Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion 2013; 53:2340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das-Gupta E, Dignan F, Shaw B, et al. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. Bone Marrow Transplant 2014; 49:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YB, Perales MA, Li S, et al. Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood 2017; 129:3256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005; 130:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Socié G, Vigouroux S, Yakoub-Agha I, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood 2017; 129:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006; 135:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104:1559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17:1862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnitzler M, Hasskarl J, Egger M, et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009; 15:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008; 371:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin PJ, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease involving the liver and gut: Results of a randomized, placebo controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010; 16:S169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringdén O, Gustafsson B, Sadeghi B. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease. Front Immunol 2020; 11:567210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringden O, Baygan A, Remberger M, et al. Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. Stem Cells Transl Med 2018; 7:325.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3543 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31846439" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19667266" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27903524" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Graft-versus-host disease targets ovary and causes female infertility in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22510384" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22533831" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diagnosis and management of acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32004485" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27892949" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11100278" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25170121" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25170121" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34971577" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18042798" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19443659" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9649455" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17244684" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23892326" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19285626" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22773121" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nutritional support in patients with GVHD of the digestive tract: state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9363865" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959906" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9644703" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Octreotide in the management of diarrhea induced by graft versus host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32320566" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32320566" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26228813" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28344057" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32160294" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23376495" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17234737" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : How I treat refractory acute GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25682602" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746766" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001082" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6337655" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : High dose bolus methylprednisolone for the treatment of acute graft versus host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6367162" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6377502" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevention and treatment of acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3513012" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22034658" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27721370" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ruxolitinib treatment for GvHD in patients with myelofibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15182339" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19377515" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16001244" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16443558" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16937391" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16699531" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806135" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23588536" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15837980" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pentostatin in steroid-refractory acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22203983" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437593" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27223109" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Response of Steroid-Refractory Acute GVHD toα1-Antitrypsin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11773890" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12164800" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Extracorporeal photochemotherapy for the treatment of graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23623892" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22922407" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11001894" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16757968" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9233700" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9701389" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9787144" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764513" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23534380" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23305044" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24887389" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28473406" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16098072" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27899357" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16984386" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15138163" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21745454" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19589480" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17932417" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18468526" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Mesenchymal stem cells as cellular immunosuppressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15121408" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16732175" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18468541" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease involving the liver and gut: Results of a randomized, placebo controlled, multicenter phase III trial in GVHD
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19539211" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33193339" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29533533" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
